Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for WISP1/CCN4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WISP1/CCN4 Full-Length Protein Four-domain architecture (IGFBP-VWC-TSP1-CT). HEK293 Expressed, Sequence Verified, >95% purity, Endotoxin <1EU/μg. |
View WISP1 Products |
| Domain Mapping | WISP1 Individual Domains (IGFBP, VWC, TSP1, CT) For epitope binning and functional mapping. Theoretical MW verified. |
View WISP1 Products |
| Gene Delivery | WISP1 Lentivirus Premade Particles Full-length ORF for stable fibroblast overexpression. Native glycosylation pattern. |
View WISP1 Products |
| Benchmark Ab | Anti-WISP1 (Sequence of Benchmark) Recombinant positive control for assay development. |
View WISP1 Products |
| Validator | WISP1 siRNA Set (3 target-specific) For knockdown verification and specificity controls. |
View WISP1 Products |
| CCN2/CTGF | CCN2/CTGF (Connective Tissue Growth Factor) Critical off-target family member for selectivity screening in fibrosis. |
View CCN2 Products |
| CCN1/CYR61 | CCN1/CYR61 Protein Angiogenesis-related CCN family control for cross-reactivity panels. |
View CCN1 Products |
| TGFBR1 | TGFBR1 ECD Protein Upstream signaling node in fibrosis pathway synergy analysis. |
View TGFBR1 Products |
| Integrin alpha V beta 3 | Known interaction partner mediating adhesion and migration. | View Integrin alpha V beta 3 Products |
| TLR4 | Receptor involved in WISP1-mediated inflammatory signaling. | View TLR4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CCN Family Selectivity & Cross-Reactivity (CCN1-6 share 30-50% homology) | Purified CCN1, CCN2, CCN3, CCN5, CCN6 orthologs available for cross-screening; Sequence Verified by Mass Spec. Homolog panel proteins (CCN1-6) strictly verified. |
| Domain-Specific Epitope Mapping | Modular domain proteins (IGFBP, VWC, TSP1, CT) for precise binding site determination and functional domain exclusion. |
| ECM Binding Kinetics & Cross-species Evaluation | High-concentration stable proteins (>95%) for avidity characterization in matrix-rich environments; Human/Mouse/Cyno orthologs available. |
| Functional Validation & False Positives | Validated siRNA included for target-specificity confirmation in TGF-β induced fibroblast activation assays; Recombinant Benchmark Antibodies included. |
Live WISP1/CCN4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for WISP1/CCN4 therapeutics is intensifying as the pharmaceutical industry pivots toward stromal-targeting strategies in fibrotic diseases. As a matricellular protein, WISP1 promotes cell proliferation, extracellular matrix remodeling, and epithelial-mesenchymal transition (EMT). Unlike the extensively validated CCN2/CTGF, WISP1 represents a next-generation target with distinct roles in EMT and tissue remodeling. First-generation interventions are focusing on neutralizing monoclonal antibodies to disrupt its interaction with integrins (e.g., αVβ3, α5β1) and Toll-like receptors (TLR4). The next wave of R&D is targeting domain-specific inhibition and combination approaches with TGF-β pathway modulators to treat idiopathic pulmonary fibrosis (IPF), liver fibrosis, diabetic nephropathy, and tumor microenvironment immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Bristol Myers Squibb, Early-stage Biotech, Academic Consortia | IPF, Pulmonary Fibrosis, Liver Fibrosis, Diabetic Nephropathy, Oncology | Domain-specific binding (Need modular IGFBP/VWC/TSP1 domain proteins for epitope mapping) |
| RNAi / Antisense | Academic / Preclinical | Osteoarthritis, Fibrosis | Knockdown Validation (Need Sequence Verified siRNA) |
| Bispecific Antibody | Emerging Biotech | Solid Tumors (Stroma targeting) | Cross-reactivity Panel (Need CCN1-6 family proteins for selectivity validation) |
| Domain Inhibitors (Peptide) | Research Institutes | Corneal Fibrosis, Wound Healing | Structure-Activity Relationship (Need truncated domain mutants) |
| Biomarker Assays | Diagnostics Companies | Prognostic Oncology | ELISA Development (Need Endotoxin Controlled Antigens) |